Literature DB >> 28031356

Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer.

Keiichi Jingu1, Rei Umezawa1, Takaya Yamamoto1, Haruo Matsushita1, Youjirou Ishikawa1, Maiko Kozumi1, Masaki Kubozono1, Noriyoshi Takahashi1, Noriyuki Kadoya1, Ken Takeda1.   

Abstract

PURPOSE: The purposes of the present study were to evaluate prognostic factors for patients with postoperative loco-regional recurrent esophageal cancer treated with chemoradiotherapy by multivariate analysis and to determine which irradiation is better, involved field irradiation or elective nodal irradiation, by matched-pair analysis.
METHODS: We reviewed records for 80 patients with postoperative loco-regional recurrent esophageal cancer treated by chemoradiotherapy between 2000 and 2014. The median follow-up period was 62.0 months. Thirty-one cases were treated with elective nodal irradiation and were randomly matched by risk factors to 49 cases treated with involved field irradiation (1:1).
RESULTS: Fifty-one patients had disease recurrence again, and irradiated-field failure was observed in 26 patients. The 5-year overall survival rate was 30.5% with a median survival period of 26.5 months. Grade 3 or higher late toxicity was observed in only one patient. In multivariate analysis, short disease-free interval and anastomotic recurrence were statistically significant unfavorable prognostic factors for overall survival (hazard ratios: 2.1 and 2.5, respectively). Matched-pair analysis including disease-free interval, pattern of recurrence and number of recurrent regions revealed that overall survival rate and irradiated-field control rate in patients treated with involved field irradiation were significantly better than those in patients treated with elective nodal irradiation (P = 0.016 and P = 0.014, respectively).
CONCLUSIONS: Short disease-free interval and anastomotic recurrence are unfavorable factors and elective nodal irradiation is not necessary in chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal cancer.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  chemoradiotherapy; involved field irradiation; postoperative loco-regional recurrent esophageal cancer; prognostic factor

Mesh:

Year:  2017        PMID: 28031356     DOI: 10.1093/jjco/hyw195

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

Review 1.  Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in Japan.

Authors:  Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Noriyoshi Takahashi; Kazuya Takeda; Yu Suzuki; Keita Kishida; So Omata; Yuta Sato; Noriyuki Kadoya
Journal:  Esophagus       Date:  2022-05-16       Impact factor: 3.671

Review 2.  Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.

Authors:  Dorota Gabrys; Roland Kulik; Agnieszka Namysł-Kaletka
Journal:  Br J Radiol       Date:  2021-12-08       Impact factor: 3.629

3.  Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer.

Authors:  Terufumi Kawamoto; Keiji Nihei; Keisuke Sasai; Katsuyuki Karasawa
Journal:  Esophagus       Date:  2018-05-30       Impact factor: 4.230

4.  Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study.

Authors:  Keiichi Jingu; Yuzuru Niibe; Hideomi Yamashita; Kuniaki Katsui; Toshihiko Matsumoto; Tomohiro Nishina; Atsuro Terahara
Journal:  Radiat Oncol       Date:  2017-09-05       Impact factor: 3.481

5.  Outcomes and Prognostic Factors of Salvage Radiation for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma.

Authors:  Chi Zhang; Xiao-Lin Ge; Chen-Jun Huang; Shu Zhang; Xin-Chen Sun
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.